2020
Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside
Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal Of Leukocyte Biology 2020, 108: 1455-1489. PMID: 32557857, DOI: 10.1002/jlb.5bt0420-585rr.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMode of deliveryCancer vaccinesImmune checkpoint blockade agentsCheckpoint blockade agentsDifferent cancer vaccinesNeoantigen-based vaccinesRecent preclinical advancesCancer vaccine trialsCancer vaccine fieldLittle clinical activityPromising preclinical resultsMultiple cancer typesCheckpoint blockadeImmunotherapeutic trialsPreclinical advancesTherapeutic vaccinesVaccine trialsClinical activityPreclinical resultsClinical strategiesTherapeutic outcomesVaccine fieldClinical effortsVaccineCancer types
2015
Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials’ experience
Ramirez A, Wages N, Hu Y, Smolkin M, Slingluff C. Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials’ experience. Cancer Immunology, Immunotherapy 2015, 64: 1531-1539. PMID: 26392296, PMCID: PMC4644444, DOI: 10.1007/s00262-015-1758-5.Peer-Reviewed Original ResearchConceptsDisease-free survivalT cell responsesOverall survivalImmune responseOlder patientsCancer vaccinesClinical outcomesResected stage IIB-IV melanomaCD8+ T cell responsesStage IIB-IV melanomaLonger disease-free survivalImpact of patient ageMelanoma-associated peptidesCancer vaccine trialsClinical trial experienceIncidence of IRCumulative incidence rateKaplan-Meier estimatesClass I MHCMelanoma vaccineMenopausal statusPatient ageSurvival outcomesStratify patientsFemale patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply